Blueprint Medicines has completed its acquisition of Lengo Therapeutics. The company develops therapeutics targeting driver mutations in oncology. The deal is worth $250 million. Blueprint will also pay an additional $215 million if LNG-451, a drug that could potentially treat non-small cell lung cancer patients with exon insertion mutations, reaches certain milestones.